Publications by authors named "Maria L Musumeci"

Claim this Profile
S
Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study.
Riccardo Balestri, Giulia Odorici, Michela Magnano, Paolo Gisondi, Francesco Bellinato, Maria Letizia Musumeci

J Eur Acad Dermatol Venereol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study.
Francesca Barei, Stefano Macchi, Paolo Calzari, Simone Ribero, Michela Ortoncelli, Maria Letizia Musumeci

Clin Exp Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).
Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, Antonio Costanzo, Matteo Bianco, Maria Letizia Musumeci

Dermatol Ther (Heidelb)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraclass Switching of IL-23 Inhibitors in Psoriasis: Effectiveness, Patterns, and Predictors of Response - A Retrospective Multicenter Study in Italy.
Giacomo Caldarola, Eleonora De Luca, Anna Balato, Martina Burlando, Andrea Carugno, Maria Letizia Musumeci

Clin Exp Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational Study.
Giuseppe Lauletta, Cataldo Patruno, Luca Potestio, Michela Ortoncelli, Simone Ribero, Maria Letizia Musumeci

Clin Exp Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brodalumab Efficacy in Psoriasis Patients with Inadequate Response to IL-23 or IL-12/23 Inhibitors: Multicenter Italian Retrospective Analysis - IL PSO (Italian Landscape Psoriasis).
Diego Orsini, Maria Concetta Fargnoli, Martina Burlando, Anna Campanati, Elena Campione, Attilia Musumeci, Maria Letizia Musumeci

Dermatol Pract Concept· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study.
Luigi Gargiulo, Silvia M Ferrucci, Luciano Ibba, Ruggero Cascio Ingurgio, Angela Alfano, Maria L Musumeci

J Eur Acad Dermatol Venereol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis).
Diego Orsini, Dario Graceffa, Martina Burlando, Anna Campanati, Elena Campione, Attilia Musumeci, Maria Letizia Musumeci

Clin Exp Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis).
Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Maria L Musumeci

Dermatol Ther (Heidelb)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD.
Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, Silvia Mariel Ferrucci, Luisa Angileri, Maria Letizia Musumeci

Dermatitis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience.
Cristina Bertoli, Tiago Torres, Paolo Romita, Luca Stingeni, Katharina Hansel, Maria Letizia Musumeci

Psoriasis (Auckl)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ixekizumab in psoriatic patients: a long-term real-world retrospective multicentre study from Southern Italy.
Maria Letizia Musumeci, Andrea Calogero Trecarichi, Matteo Megna, Luca Potestio, Giuseppe Micali

Clin Exp Dermatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world study.
Annunziata Raimondo, Paolo Amerio, Anna Balato, Francesco Cusano, Maria Concetta Fargnoli, Maria Letizia Musumeci

J Eur Acad Dermatol Venereol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term efficacy of tildrakizumab on difficult-to-treat areas: a real-world experience.
Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Maria Letizia Musumeci, Giacomo Caldarola

Int J Dermatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis).
Diego Orsini, Dario Graceffa, Martina Burlando, Anna Campanati, Elena Campione, Attilia Musumeci, Maria Letizia Musumeci

J Clin Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Line-Field Confocal Optical Coherence Tomography Imaging of Psoriasis With Histopathology Correlation.
Anna Elisa Verzì, Francesco Lacarrubba, Maria Letizia Musumeci, Rosario Caltabiano, Giuseppe Micali

J Cutan Pathol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Fabrizio Amoruso, Maria L Musumeci

J Dermatolog Treat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis).
Luigi Gargiulo, Luciano Ibba, Angela Alfano, Piergiorgio Malagoli, Fabrizio Amoruso, Maria L Musumeci

J Dermatolog Treat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients.
Silvia Ferrucci, Simona Tavecchio, Carlo Alberto Maronese, Anna Balato, Eugenia Veronica Di Brizzi, Maria Letizia Musumeci

Clin Exp Dermatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of registered clinical trials in Italy regarding dermatology (2003-2022): a cross-sectional study on historical trend and prospects for industry investments.
Pino Fioravanti, Patrizia Mascagni, Giulia Rosso, Roberta Montisci, Maria L Musumeci

Ital J Dermatol Venerol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study.
Elena Campione, Fabio Artosi, Ruslana Gaeta Shumak, Alessandro Giunta, Giuseppe Argenziano, Maria Letizia Musumeci

Pharmaceuticals (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contact allergy to SIDAPA baseline series allergens in patients with eyelid dermatitis: An Italian multicentre study.
Luca Stingeni, Caterina Foti, Fabrizio Guarneri, Monica Corazza, Antonio Cristaudo, Maria Letizia Musumeci

Contact Dermatitis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Attachment Style and Temperament Traits on the Quality of Life of Patients with Psoriasis.
Maria Luisa Pistorio, Tania Moretta, Maria Letizia Musumeci, Claudia Russo, Francesco Lacarrubba

Behav Sci (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.
Filomena Russo, Marco Galluzzo, Luca Stingeni, Severino Persechino, Leonardo Zichichi, Maria Letizia Musumeci

Clin Cosmet Investig Dermatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis.
Eugenia Veronica Di Brizzi, Dario Buononato, Pierfrancesco Benvenuto, Giuseppe Argenziano, Rocco De Pasquale, Maria Letizia Musumeci

Dermatol Pract Concept· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis